Key Highlights
- Veradermics shares closed up 12% at $123.70 after revealing successful topline data from its Phase 2 Study 207 trial testing VDPHL01 for female pattern hair loss.
- The trial achieved its primary endpoints over six months, with 4.5mg QD and BID cohorts showing significant mean target area hair count gains of 22.7 and 23.3 hairs per square centimeter, respectively.
- Approximately 90% of subjects reported improved coverage via the AAIRS scale by the study's conclusion, with clinical activity noted as early as the second month.
- The therapy showed a favorable safety profile with no drug-related serious adverse events or cardiac complications, and the company now carries a market capitalization of approximately $5.17 billion.
Veradermics, Incorporated (NYSE: MANE) shares rose 12% to close at $123.70 after the company revealed successful topline data from its Phase 2 Study 207, an open-label trial testing VDPHL01 for female pattern hair loss, a common and often distressing condition affecting a significant proportion of women, particularly as they age.
VDPHL01 is a specialized gel-matrix oral minoxidil engineered for extended release, designed to sustain therapeutic growth-promoting levels of the drug while mitigating cardiovascular risks that have historically been linked to traditional immediate-release oral minoxidil formulations. This extended-release engineering approach represents an important potential advancement, as oral minoxidil has gained popularity for hair loss treatment in recent years but carries cardiovascular safety considerations that a more controlled delivery profile may help address.
The trial successfully achieved its primary endpoints over a six-month treatment period, with the 4.5mg once-daily (QD) and twice-daily (BID) cohorts showing significant mean target area hair count (TAHC) gains of 22.7 and 23.3 hairs per square centimeter, respectively. These hair count improvements represent a clinically meaningful and quantifiable measure of treatment efficacy in a condition where visible, measurable hair regrowth is the primary outcome patients and physicians are seeking.
Clinical activity was noted as early as the second month of treatment, suggesting a relatively rapid onset of therapeutic effect, and by the study's conclusion, approximately 90% of subjects reported improved coverage via the AAIRS scale, indicating that the quantitative hair count improvements translated into meaningful, patient-perceived visual improvement in hair coverage.
Critically for a therapy built around addressing the cardiovascular safety concerns associated with oral minoxidil, the trial showed a favorable safety profile with no drug-related serious adverse events or cardiac complications reported. This safety outcome is central to VDPHL01's value proposition, as demonstrating that the extended-release formulation successfully avoids the cardiovascular risks associated with immediate-release oral minoxidil is essential to the drug's differentiated positioning.
With today's gain, Veradermics now carries a market capitalization of approximately $5.17 billion, reflecting substantial investor confidence in VDPHL01's commercial prospects. Building on these encouraging Phase 2 results, the company is progressing with its Phase 2/3 Study 306, with a topline readout anticipated during the first half of 2027 — the next critical step in confirming whether the strong efficacy and safety signals observed in Study 207 hold up in a larger, more rigorously controlled trial setting ahead of any potential regulatory filing.






Please wait processing your request...